Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Input: Consider Input: Paragraph: Limiting the quantity per dosage unit will reduce the risk of inadvertent overdose, which can lead to liver failure, liver transplant and death, the Food and Drug Administration said. It cited the fact that no available data showed that taking more than the recommended dose provided benefits that outweighed the added risks. (link.reuters.com/nen95v)  Inadvertent overdose from combination drugs containing acetaminophen, also known as paracetamol in most countries outside the United States, accounts for nearly half of all cases of acetaminophen-related liver failure in the United States, the agency said. Combination acetaminophen products are commonly prescribed to patients to treat pain from acute injuries, post-operative pain, or pain following dental procedures. In January 2011, the FDA asked manufacturers of combination drugs containing acetaminophen, sold globally under trade names such as Tylenol and Panadol, to limit acetaminophen doses to no more than 325 mg in each tablet or capsule by January 14, 2014. (link.reuters.com/hyn95v)  Some of these products still remain available, the agency said. The FDA also suggested that pharmacists who receive a prescription for a combination product with more than the recommended dose contact the prescriber to discuss using a lower dose. In the near future, the FDA plans to institute proceedings to withdraw approval for combination drugs that remain on the market, it said in a statement. Acetaminophen, one of the most commonly used drugs in the United States, is widely used in both prescription and over-the-counter products to reduce pain and fever. Claim: FDA asks doctors to limit acetaminophen in combination drugs.

Output: U.S. health regulators recommended on Tuesday that healthcare professionals stop prescribing combination drugs that contain more than 325 milligrams of acetaminophen per tablet, capsule, or other dosage unit, citing the risk of liver damage.


Input: Consider Input: Paragraph: Keytruda is already approved as a cost-effective treatment in melanoma and the National Institute for Health and Care Excellence also on Dec. 2 approved its use in the treatment of lung cancer patients who had started on chemotherapy, after Merck & Co cut the price further for the NHS. But trial data so far on the survival benefit of Keytruda as an initial lung cancer treatment has not been reliable enough,   according to NICE’s draft guidance, which will be subject to public consultation until 21 March. “The exact size of the overall survival gain for Keytruda compared to the current standard of care was uncertain because of the immaturity of the data,” a NICE spokeswoman said. Keytruda has proved effective in fighting non-small cell lung cancer in patients with high levels of a protein called PD-L1, which makes them more receptive to immunotherapy. The average cost of a course of treatment in Britain is around 29,000 pounds ($36,000) at the full list price but the NHS will pay less after getting a confidential discount. ($1 = 0.8042 pounds) Claim: UK rejects Merck's Keytruda as initial treatment for lung cancer.

Output: Britain’s healthcare watchdog NICE, which assesses the cost-effectiveness of medical treatments, has stopped short of recommending the use by the National Health Service (NHS) of Merck & Co Inc’s immunotherapy drug Keytruda in newly diagnosed lung cancer patients, after giving the go-ahead in December for patients who had prior treatment.


Input: Consider Input: Paragraph: The story goes into some detail about the cost of Folotyn, which is extraordinarily high. The story also does a great job of comparing the cost of the drug to other expensive cancer drugs. Costs were the main focus of the story. The story adequately quantitifes the benefits of Folotyn, which are not that impressive. The story provides the percentage of patients with reductions in tumor size and the median time that the benefits lasted. The story does not mention any potential harms of Folotyn. Although the primary focus of the story realtes to the drug’s cost, it would have desriable to provide a brief comment on the toxicity of the drug as well. The addition of the information would help the reader place the value of the drug into a better perspective. According to the package insert, 44% of patients treated in the clinical trial suffered from a serious side effect of the drug The story describes the evidence to support Folotyn, which is rather thin. The story mentions one clinical trial that showed a reduction in tumor size in some participants, but that to date, the drug has not been shown to prolong longevity. The quote from a member of the FDA advisory board that recommended approval provides an excellent overview and counterpoint to the comments of the company spokesperson. The story accurately represents the seriousness and prevalence of peripheral T-cell Lymphoma, which is quite rare and serious. The story quotes multiple stakeholders, including experts from the drug manufacturer, a large insurance company, and lymphoma researchers. The provide valuable diversity of perspectives on this controversial issue. The story clearly states that there are no alternatives to Folotyn for this particular indications, but compares the price of the drug to several other expensive cancer drugs. The story should have emphasized that Folotyn was studied in patients who have relapsed and a comparison with currently used regimens is not available. The story clearly states that Folotyn is not currently available but that the manufacturer plans to market the drug in January. The story clearly states that Folotyn is new. It could have stated that a host of older and less expensive treatment options are currently available. Because the story quotes mutliple experts, the reader can assume the story did not rely on a press release as the sole source of information. Claim: Questioning a $30,000-a-Month Cancer Drug


Output: This story focuses on issue of the cost of a new cancer drug, but it also provides valuable and balanced information for the reader on the drug, Fotolyn, in terms of its potential benefits, availability, novelty, and evidence to support its use. Notably, the story quotes multiple stakeholders, including experts from the drug manufacturer, a large insurance company, and lymphoma researchers. These quotes provide diversity of perspectives on this controversial issue. Recent debates on health care reform in the United States have highlighted the complex problem of cost of drugs and treatments. Healthcare costs are rising at alarming rates, causing a significant drag on our economy. How much is too much to spend on a new drug? The recent news of the FDA approval of Folotyn, a chemotherapy drug for peripheral T-cell lymphoma, a rare and serious cancer, has raised this question in dramatic fashion. Folotyn is projected to cost $30,000 per month, quite a bit higher than other high priced cancer drugs. Folotyn is projected to be a money-maker for the manufacturer, Allos Therapeutics.